Moffitt Cancer Center is a major contributor to the developing biotechnology industry in the greater Tampa Bay area. Over the years, Moffitt researchers have made several exciting scientific discoveries. Please click on the following links to read more about Moffitt programs and initiatives that contribute to the biotech industry.
Media Coverage • Moffitt Headline News • Press Releases
Business of Biotech – Moffitt's Office of Technology Management and Licensing (OTML) holds its annual Business of Biotech meeting each year, and the topics include new opportunities for technology licensing at Moffitt and new technologies in commercial development at Moffitt.
Total Cancer CareTM – This comprehensive approach to cancer enables researchers and care-givers to identify and meet all the needs of a patient and their family during the patient's lifetime and for future generations.
M2Gen – M2Gen is the result of a partnership formed in December 2006 between H. Lee Moffitt Cancer Center & Research Institute and drug maker Merck & Co. The for-profit company will develop personalized cancer treatments for patients using molecular technology.
Moffitt Research Institute – Moffitt Cancer Center & Research Institute began its research efforts in 1993 and by 1998 achieved National Cancer Institute (NCI) designation. Today, research at Moffitt includes more than 135 investigators organized around six scientific programs, all with an emphasis on translation. In October 2006, the NCI renewed Moffitt’s Comprehensive Cancer Center status and its Cancer Center Support Grant for five years.
Office of Technology Management and Commercialization (OTMC) – OTMC provides personnel at H. Lee Moffitt Cancer Center & Research Institute with assistance in matters relating to intellectual property and technology management. OTMC identifies, protects and commercializes novel technologies that will contribute to the prevention, detection and cure of cancer.
National Functional Genomics Center (NFGC) – Mission: The National Functional Genomics Center (NFGC) will validate the concept that molecular signatures in tumors predict cancer risk, diagnosis, prognosis, and response to therapy, as well as identify new molecular targets for the development of more effective cancer prevention and personalized therapeutic care.
Integrated Mathematical Oncology – The IMO is partly funded by the NCI Integrative Cancer Biology Program (ICBP), which is focused on the analysis of cancer as a complex biological system. With the cornerstones of integration and computation, the program brings together a multidisciplinary community of researchers to work on key questions in cancer biology.
Jarett Rieger, Esq., MBA – Director of OTML and Associate General Counsel
© Copyright 1996 - 2013 H. Lee Moffitt Cancer Center & Research Institute